By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

HepaRegeniX GmbH 



Tubingen       Germany
Phone: n/a Fax: n/a


SEARCH JOBS

HepaRegeniX, founded in 2015, specializes in the discovery and development of small molecule kinase inhibitors. The management team, led by Dr. Wolfgang Albrecht, and scientific advisors have over 20 years of experience in the pharmaceutical industry with a proven track record in drug development and cover all disciplines along the value creation chain from early stage discovery through clinical proof-of-concept studies. The unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo A/S, coparion, High-Tech Gruenderfonds and Ascenion GmbH. Ascenion supported the acquisition of the exclusive IP rights.

YEAR FOUNDED:

2015

LEADERSHIP:

CEO: Wolfgang Albrecht


Key Statistics


Email:
Ownership: Private

Web Site: HepaRegeniX GmbH
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->